Cellular Biomedicine Group Announces Positive 48-Week Data From Phase IIb Clinical Trial for Knee Osteoarthritis Stem Cell ReJoin® Therapy
13 janv. 2016 08h00 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Announces Upcoming Presentation to Release 48-Week Data From Phase IIb Clinical Trial for Knee Osteoarthritis ReJoin® Stem Cell Therapy
22 déc. 2015 09h00 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...